These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3099273)

  • 1. Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud's phenomenon.
    Coppock JS; Hardman JM; Bacon PA; Woods KL; Kendall MJ
    Postgrad Med J; 1986 Jan; 62(723):15-8. PubMed ID: 3099273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease.
    Franks AG
    Lancet; 1982 Jan; 1(8263):76-7. PubMed ID: 6119495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.
    Teh LS; Manning J; Moore T; Tully MP; O'Reilly D; Jayson MI
    Br J Rheumatol; 1995 Jul; 34(7):636-41. PubMed ID: 7670782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical nitroglycerin ointment in Raynaud's phenomenon.
    Fischer M; Reinhold B; Falck H; Török M; Alexander K
    Z Kardiol; 1985 May; 74(5):298-302. PubMed ID: 3925656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of digital artery adrenoceptors in Raynaud's disease.
    Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
    Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm.
    Wigley FM; Wise RA; Malamet R; Scott TE
    Arthritis Rheum; 1987 Mar; 30(3):281-6. PubMed ID: 2952125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [How I treat...Raynaud's phenomenon].
    Piérard GE
    Rev Med Liege; 1998 Mar; 53(3):119-20. PubMed ID: 9594609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Raynaud's phenomenon with calcium channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Med; 1985 Feb; 78(2B):39-42. PubMed ID: 3976694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis.
    Anderson ME; Moore TL; Hollis S; Jayson MI; King TA; Herrick AL
    Rheumatology (Oxford); 2002 Mar; 41(3):324-8. PubMed ID: 11934971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon.
    Belch JJ; Madhok R; Shaw B; Leiberman P; Sturrock RD; Forbes CD
    Lancet; 1985 May; 1(8439):1180-3. PubMed ID: 2860386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon.
    Creager MA; Pariser KM; Winston EM; Rasmussen HM; Miller KB; Coffman JD
    Am Heart J; 1984 Aug; 108(2):370-3. PubMed ID: 6380254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raynaud's phenomenon of the lung.
    Fahey PJ; Utell MJ; Condemi JJ; Green R; Hyde RW
    Am J Med; 1984 Feb; 76(2):263-9. PubMed ID: 6695950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactive hyperemia in patients with Raynaud's phenomenon.
    Russell A; Kappagoda T
    J Rheumatol; 1988 Nov; 15(11):1653-7. PubMed ID: 3236299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
    Dormandy JA; Berent A; Downes SJ
    Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nifedipine as a therapeutic modality for Raynaud's phenomenon.
    Winston EL; Pariser KM; Miller KB; Salem DN; Creager MA
    Arthritis Rheum; 1983 Oct; 26(10):1177-80. PubMed ID: 6626276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
    Sunderland GT; Belch JJ; Sturrock RD; Forbes CD; McKay AJ
    Clin Rheumatol; 1988 Mar; 7(1):46-9. PubMed ID: 3044673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial.
    Wise RA; Malamet R; Wigley FM
    J Rheumatol; 1987 Apr; 14(2):278-83. PubMed ID: 3298649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A; McCans J; Willan AR; Ford PM
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.